Mengjia Lin

机构：Zhejiang University

发表论文 9 篇 · 总被引 69 次 · h-index 4

代表论文

• A pan-KRAS inhibitor and its derived degrader elicit multifaceted anti-tumor efficacy in KRAS-driven cancers (2025 · Cancer Cell · 被引 29)
• Identification of osalmid metabolic profile and active metabolites with anti-tumor activity in human hepatocellular carcinoma cells (2020 · Biomedicine & Pharmacotherapy · 被引 16)
• A dual-layer cell-laden tubular scaffold for bile duct regeneration (2021 · Materials & Design · 被引 15)
• A novel multitarget kinase inhibitor BZG with potent anticancer activity in vitro and vivo enhances efficacy of sorafenib through PI3K pathways in hepatocellular carcinoma cells (2020 · Biomedicine & Pharmacotherapy · 被引 9)
• The NuA4 Acetyltransferase, Acetylation of Histone H4 and the H2A.Z Variant Histone are Required for Appropriate RNA Splicing in Saccharomyces cerevisiae (2022 · The FASEB Journal)
• The Histone H4 Acetyltransferase NuA4 is Required for Appropriate RNA Splicing in Saccharomyces cerevisiae (2019 · The FASEB Journal)